NUVATION BIO INC (NUVB) Fundamental Analysis & Valuation

NYSE:NUVB • US67080N1019

4.81 USD
+0.08 (+1.69%)
Last: Mar 10, 2026, 11:44 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NUVB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall NUVB gets a fundamental rating of 2 out of 10. We evaluated NUVB against 193 industry peers in the Pharmaceuticals industry. NUVB has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NUVB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. NUVB Profitability Analysis

1.1 Basic Checks

  • In the past year NUVB has reported negative net income.
  • In the past year NUVB has reported a negative cash flow from operations.
  • NUVB had negative earnings in each of the past 5 years.
  • NUVB had a negative operating cash flow in each of the past 5 years.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M -500M

1.2 Ratios

  • NUVB has a Return On Assets of -34.40%. This is comparable to the rest of the industry: NUVB outperforms 45.60% of its industry peers.
  • NUVB's Return On Equity of -66.93% is in line compared to the rest of the industry. NUVB outperforms 42.49% of its industry peers.
Industry RankSector Rank
ROA -34.4%
ROE -66.93%
ROIC N/A
ROA(3y)-50.55%
ROA(5y)-35.67%
ROE(3y)-67.31%
ROE(5y)-45.89%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • NUVB's Gross Margin of 85.22% is amongst the best of the industry. NUVB outperforms 87.56% of its industry peers.
  • The Profit Margin and Operating Margin are not available for NUVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NUVB Health Analysis

2.1 Basic Checks

  • NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NUVB has been increased compared to 1 year ago.
  • Compared to 5 years ago, NUVB has more shares outstanding
  • Compared to 1 year ago, NUVB has a worse debt to assets ratio.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 0.65, we must say that NUVB is in the distress zone and has some risk of bankruptcy.
  • NUVB's Altman-Z score of 0.65 is in line compared to the rest of the industry. NUVB outperforms 53.89% of its industry peers.
  • NUVB has a Debt/Equity ratio of 0.65. This is a neutral value indicating NUVB is somewhat dependend on debt financing.
  • NUVB has a worse Debt to Equity ratio (0.65) than 66.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z 0.65
ROIC/WACCN/A
WACC9.18%
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.95 indicates that NUVB has no problem at all paying its short term obligations.
  • NUVB's Current ratio of 6.95 is fine compared to the rest of the industry. NUVB outperforms 72.54% of its industry peers.
  • NUVB has a Quick Ratio of 6.81. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NUVB (6.81) is better than 72.02% of its industry peers.
Industry RankSector Rank
Current Ratio 6.95
Quick Ratio 6.81
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NUVB Growth Analysis

3.1 Past

  • NUVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.38%.
  • NUVB shows a strong growth in Revenue. In the last year, the Revenue has grown by 698.96%.
EPS 1Y (TTM)-15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)698.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%633.15%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.39% on average over the next years. This is quite good.
  • NUVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.51% yearly.
EPS Next Y16.92%
EPS Next 2Y37.04%
EPS Next 3Y50.53%
EPS Next 5Y16.39%
Revenue Next Year196.53%
Revenue Next 2Y138.5%
Revenue Next 3Y101.57%
Revenue Next 5Y66.51%

3.3 Evolution

NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. NUVB Valuation Analysis

4.1 Price/Earnings Ratio

  • NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • NUVB's earnings are expected to grow with 50.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.04%
EPS Next 3Y50.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NUVB Dividend Analysis

5.1 Amount

  • No dividends for NUVB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NUVB Fundamentals: All Metrics, Ratios and Statistics

NUVATION BIO INC

NYSE:NUVB (3/10/2026, 11:44:04 AM)

4.81

+0.08 (+1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-05
Inst Owners63%
Inst Owner Change-7.93%
Ins Owners17.92%
Ins Owner Change0.04%
Market Cap1.65B
Revenue(TTM)62.90M
Net Income(TTM)-204.63M
Analysts82.35
Price Target12.14 (152.39%)
Short Float %17.69%
Short Ratio8.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.85%
Min EPS beat(2)-20.68%
Max EPS beat(2)6.98%
EPS beat(4)3
Avg EPS beat(4)-2.98%
Min EPS beat(4)-20.68%
Max EPS beat(4)6.98%
EPS beat(8)4
Avg EPS beat(8)-19.33%
EPS beat(12)8
Avg EPS beat(12)-5.68%
EPS beat(16)11
Avg EPS beat(16)-1.47%
Revenue beat(2)2
Avg Revenue beat(2)52.23%
Min Revenue beat(2)9.97%
Max Revenue beat(2)94.49%
Revenue beat(4)4
Avg Revenue beat(4)489.2%
Min Revenue beat(4)9.97%
Max Revenue beat(4)1226.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.39%
PT rev (3m)13.94%
EPS NQ rev (1m)5.76%
EPS NQ rev (3m)12.05%
EPS NY rev (1m)1.21%
EPS NY rev (3m)2.51%
Revenue NQ rev (1m)5.76%
Revenue NQ rev (3m)13.43%
Revenue NY rev (1m)3.38%
Revenue NY rev (3m)7.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.22
P/FCF N/A
P/OCF N/A
P/B 5.39
P/tB 5.6
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.18
BVpS0.89
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.4%
ROE -66.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.22%
FCFM N/A
ROA(3y)-50.55%
ROA(5y)-35.67%
ROE(3y)-67.31%
ROE(5y)-45.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 480.39%
Cap/Sales 13.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.95
Quick Ratio 6.81
Altman-Z 0.65
F-Score4
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)178.4%
Cap/Depr(5y)175.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y16.92%
EPS Next 2Y37.04%
EPS Next 3Y50.53%
EPS Next 5Y16.39%
Revenue 1Y (TTM)698.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%633.15%
Revenue Next Year196.53%
Revenue Next 2Y138.5%
Revenue Next 3Y101.57%
Revenue Next 5Y66.51%
EBIT growth 1Y-27.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.04%
EBIT Next 3Y22.02%
EBIT Next 5YN/A
FCF growth 1Y-39.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.98%
OCF growth 3YN/A
OCF growth 5YN/A

NUVATION BIO INC / NUVB FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NUVB.


Can you provide the valuation status for NUVATION BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to NUVATION BIO INC (NUVB). This can be considered as Overvalued.


How profitable is NUVATION BIO INC (NUVB) stock?

NUVATION BIO INC (NUVB) has a profitability rating of 1 / 10.